We are live on ! Find out more
RVNC

Revance Therapeutics, Inc.
RVNC

Delisted

RVNC was delisted on the 5th of February, 2025.

Back to rankings

80 hedge funds and large institutions have $301M invested in Revance Therapeutics, Inc. in 2014 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 40 increasing their positions, 19 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

111% more repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 19

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

18% less funds holding

Funds holding: 98 → 80 (-18)

46% less capital invested

Capital invested by funds: $556M → $301M (-$255M)

67% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 27

Holders
80
Holders Change
-18
Holders Change %
-18.37%
% of All Funds
2.32%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
9
Increased
40
Reduced
19
Closed
27
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Franklin Resources
Franklin Resources
California
+$27.1M
2
ACH
ArrowMark Colorado Holdings
Colorado
+$7.01M
3
PHS
PFM Health Sciences
California
+$3.98M
4
AllianceBernstein
AllianceBernstein
Tennessee
+$3.69M
5
JP Morgan Chase
JP Morgan Chase
New York
+$3M

Top Sellers

Rank Fund Capital Flow
1
Jennison Associates
Jennison Associates
New York
-$21.4M
2
CCM
Camber Capital Management
Massachusetts
-$21.4M
3
VAM
Visium Asset Management
New York
-$12.3M
4
DM
Deerfield Management
New York
-$8.72M
5
DCM
Driehaus Capital Management
Illinois
-$5.02M
Name Holding Trade Value Shares
Change 		Change in
Stake
ZDA
26
Zweig-DiMenna Associates
New York
$1.63M -$13K -500 -0.6%
Bank of New York Mellon
27
Bank of New York Mellon
New York
$1.62M -$663K -25,443 -23%
LCS
28
Levin Capital Strategies
New York
$1.6M -$2.66M -102,111 -55%
PAI
29
Palo Alto Investors
California
$1.55M -$295K -11,300 -12%
DCM
30
Driehaus Capital Management
Illinois
$1.44M -$5.02M -192,765 -72%
HCMT
31
Highland Capital Management (Texas)
Texas
$1.41M – – –
Principal Financial Group
32
Principal Financial Group
Iowa
$1.4M +$145K +5,581 +8%
UBS AM
33
UBS AM
Illinois
$1.26M – – –
Geode Capital Management
34
Geode Capital Management
Massachusetts
$1.22M +$578K +22,182 +54%
WSA
35
Wall Street Associates
California
$1.11M -$643K -24,680 -30%
TG
36
TCW Group
California
$1.08M -$69.1K -2,651 -5%
CCI
37
Columbus Circle Investors
$1.08M +$1.45M +55,741 New
SI
38
Standard Investments
New York
$925K +$588K +22,546 +89%
BAMCO Inc
39
BAMCO Inc
New York
$831K +$599K +23,000 +115%
PP
40
PDT Partners
New York
$813K +$163K +6,266 +18%
B
41
Baird
Wisconsin
$697K +$940K +36,078 New
Alyeska Investment Group
42
Alyeska Investment Group
Illinois
$626K -$720K -27,640 -46%
TCIM
43
TIAA CREF Investment Management
New York
$558K – – –
Citadel Advisors
44
Citadel Advisors
Florida
$533K -$2.55M -97,735 -78%
BIM
45
BlackRock Investment Management
Delaware
$509K +$126K +4,831 +22%
State of New Jersey Common Pension Fund D
46
State of New Jersey Common Pension Fund D
New Jersey
$503K – – –
SCA
47
Secor Capital Advisors
New York
$429K +$578K +22,175 New
Charles Schwab
48
Charles Schwab
California
$373K +$99.5K +3,819 +25%
NFA
49
Nationwide Fund Advisors
Ohio
$370K +$29.2K +1,120 +6%
CS
50
Credit Suisse
Switzerland
$357K +$297K +11,407 +161%
1
2
3 4 5

RVNC Hedge Fund Activity: Q3 2014 in Review

80 of the 3,448 institutional investors tracked by Wall St. Rank reported a position in Revance Therapeutics, Inc. (RVNC) for Q3 2014, worth a combined $301M — down 46% from $556M a quarter earlier.

Sellers outnumbered buyers: 27 funds closed out of RVNC and 9 opened new positions — a net loss of 18 holders — while 19 trimmed existing stakes and 40 added.

The largest buyer was Franklin Resources, adding an estimated $27.1M. The largest seller was Jennison Associates, cutting an estimated $21.4M.

  • 80 institutional investors held Revance Therapeutics, Inc. (RVNC) as of Q3 2014, down from 98 in Q2 2014.
  • Funds reported $301M of Revance Therapeutics, Inc. stock for Q3 2014, down 46% quarter-over-quarter.
  • 9 funds opened new Revance Therapeutics, Inc. positions in Q3 2014 and 27 closed out, a net change of -18 holders.
  • The largest Revance Therapeutics, Inc. buyer in Q3 2014 was Franklin Resources, an estimated $27.1M added.
  • The largest Revance Therapeutics, Inc. seller in Q3 2014 was Jennison Associates, an estimated $21.4M sold.

Based on aggregated 13F filings for Q3 2014.